The latest news, announcements and press releases from PharmaEssentia.
PharmaEssentia Corporation, a global biopharmaceutical company headquartered in Taiwan, will invest approximately $46 million to establish a new, wholly owned manufacturing subsidiary in Puerto Rico.
The planned investment supports the company’s global manufacturing expansion strategy and is intended to serve as a future manufacturing center for the U.S. market and long-term global demand for BESREMi (ropeginterferon alfa-2b).
The investment reflects sustained global demand growth for BESREMi, particularly in the United States, as well as the potential additional demand growth from regulatory approvals of BESREMi for new uses.
This is the News section of the company profile page for PharmaEssentia on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.
